Quanterix's Simoa technology represents a dramatic technological leap forward compared to traditional Enzyme-Linked Immunosorbent Assay (ELISA) methods. While traditional ELISA assays are often limited in sensitivity and struggle to detect low-abundance proteins in early disease stages, Quanterix's digital immunoassay platform isolates individual molecules on microscopic beads within femtoliter-sized wells. This methodological difference allows Quanterix to achieve a thousand-fold increase in sensitivity over conventional ELISA, enabling the precise quantification of biomarkers that were previously undetectable in blood or biofluids.